Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Sepofarsen (QR-110) in LCA10
NCT03913130Phase 2Terminated
- Sponsor
- Laboratoires Théa
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sepofarsen in Leber congenital amaurosis (LCA), sponsored by Laboratoires Théa. Primary endpoints: Frequency of Ocular Adverse Events at 24 months and Frequency of Non-ocular Adverse Events at 24 months. Started May 2019; status: terminated.
02
Drugs
sepofarsen
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT03913130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913130.